BRAF V600E is a determinant of sensitivity to proteasome inhibitors

导出原文传递

翻译打印收藏纠错

作者： Zecchin,D. ^[1] ; Boscaro,V. ^[2] ; Medico,E. ^[3] ; Barault,L. ^[4] ; Martini,M. ; Arena,S. ; Cancelliere,C. ; Bartolini,A. ; Crowley,E.H. ; Bardelli,A. ; Gallicchio,M. ; DiNicolantonio,F.

作者单位： Scienza e Tecnologia del Farmaco, University of Torino, Torino, Italy ^[1] Departments of Oncology, United States, IRCC Institute for Cancer Research and Treatment at ^[2] IRCC Institute for Cancer Research and Treatment at Candiolo, Candiolo, Italy ^[3] IRCC Institute for Cancer Research and Treatment at Candiolo, Candiolo, Italy, FIRC Institute of ^[4]

发布时间 2014-04-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Molecular cancer therapeutics

2013年12卷12期

2950-2961页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

BRAF V600E is a determinant of sensitivity to proteasome inhibitors

Molecular cancer therapeutics

相似文献

Molecular cancer therapeutics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

BRAF V600E is a determinant of sensitivity to proteasome inhibitors

Molecular cancer therapeutics

相似文献

Molecular cancer therapeutics

相关期刊

检索历史清除